Role of lymphadenectomy during primary surgery for kidney cancer

Purpose of review Lymph node dissection (LND) during radical nephrectomy (RN) for renal cell carcinoma (RCC) is not considered as a standard. The emergence of robot-assisted surgery and effective immune checkpoint inhibitors (ICI) in recent years may change this and lymph node (LN) staging has become easier and has a clinical impact. In this review, we aimed to reconsider the role of LND today. Recent findings Although the extent of LND has still not been well established, removal of more LN seems to provide better oncologic outcomes for a select group of patients with high-risk factors such as clinical T3-4. Adjuvant therapy using pembrolizumab has been shown to improve disease free survival if complete resection of metastatic lesions as well as the primary site is obtained in combination. Robot assisted RN for localized RCC has been widespread and the studies regarding LND for RCC has been recently appeared. Summary The staging and surgical benefits and its extent of LND during RN for RCC remains unclear, but it is becoming increasingly important. Technologies that allow an easier LND and adjuvant ICI that improve survival in LN-positive patients are engaging the role of LND, a procedure that was needed, but almost never done, is now indicated sometimes. Now, the goal is to identify the clinical and molecular imaging tools that can help identify with sufficient accuracy who needs a LND and which LNs to remove in a targeted personalized approach.

[1]  S. Shariat,et al.  Radical Nephrectomy After Immune Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma. , 2023, European urology focus.

[2]  B. Rini,et al.  Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial , 2022, The Lancet.

[3]  Fernando Maciel Barbosa,et al.  Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. , 2022, The Lancet. Oncology.

[4]  S. Kern,et al.  Can Retroperitoneal Lymph Node Dissection (RPLND) be feasibly performed to prolong survival in Renal Cell Carcinoma (RCC) with limited lymph node involvement? An Analysis of Recurrence Patterns. , 2022, Urologic oncology.

[5]  T. Klatte,et al.  Potential benefit of lymph node dissection during radical nephrectomy for kidney cancer: A review and critical analysis of current literature , 2022, Asian journal of urology.

[6]  Facai Zhang,et al.  The Role of Lymph Node Dissection for Non-Metastatic Renal Cell Carcinoma: An Updated Systematic Review and Meta-Analysis , 2022, Frontiers in Oncology.

[7]  Bin Yang,et al.  Prognostic Value of Positive Lymph Nodes in Patients with Renal Cell Carcinoma and Tumor Thrombus Undergoing Nephrectomy and Thrombectomy , 2021, Urologia Internationalis.

[8]  A. Finelli,et al.  Lymph node dissection during radical nephrectomy: A Canadian multi-institutional analysis. , 2021, Urologic oncology.

[9]  U. Capitanio,et al.  Outcome after resection of occult and non-occult lymph node metastases at the time of nephrectomy , 2021, World Journal of Urology.

[10]  R. Autorino,et al.  Robot-assisted Radical Nephrectomy: A Systematic Review and Meta-analysis of Comparative Studies. , 2020, European urology.

[11]  M. Araz,et al.  Is lymph node dissection necessary for staging while undergoing nephrectomy in patients with renal cell carcinoma? , 2020, Current problems in cancer.

[12]  J. Cheville,et al.  Timing and distribution of early renal cell carcinoma recurrences stratified by pathological nodal status in M0 patients at the time of nephrectomy , 2020, International journal of urology.

[13]  Hiren V. Patel,et al.  Impact of pathologic lymph node‐positive renal cell carcinoma on survival in patients without metastasis: Evidence in support of expanding the definition of stage IV kidney cancer , 2020, Cancer.

[14]  C. Amling,et al.  Survival outcomes and practice trends for off-label use of adjuvant targeted therapy in high-risk locoregional renal cell carcinoma. , 2020, Urologic oncology.

[15]  Qin Li,et al.  Reassessment of American Joint Committee on Cancer Staging for Stage III Renal Cell Carcinoma With Nodal Involvement: Propensity Score Matched Analyses of a Large Population-Based Study , 2020, Frontiers in Oncology.

[16]  Simon P. Kim,et al.  The Association of Robot-assisted Versus Pure Laparoscopic Radical Nephrectomy with Perioperative Outcomes and Hospital Costs. , 2020, European urology focus.

[17]  R. Thompson,et al.  Emulating Target Clinical Trials of Radical Nephrectomy with or without Lymph Node Dissection for Renal Cell Carcinoma. , 2020, Urology.

[18]  U. Capitanio,et al.  Topographic distribution of first landing sites of lymphatic metastases from patients with renal cancer. , 2020, Urologic oncology.

[19]  R. Thompson,et al.  The natural history of renal cell carcinoma with isolated lymph node metastases following surgical resection from 2006 to 2013. , 2019, Urologic oncology.

[20]  E. Castle,et al.  Comparison of Open and Robot Assisted Radical Nephrectomy with Level I and II Inferior Vena Cava Tumor Thrombus: The Mayo Clinic Experience. , 2019, Urology.

[21]  W. Zhuang,et al.  Valuation of lymph node dissection in localized high-risk renal cell cancer using X-tile software , 2019, International Urology and Nephrology.

[22]  V. Master,et al.  Survival benefit with extended lymphadenectomy for advanced renal malignancy: A population-based analysis , 2019, Asian journal of urology.

[23]  Mao-feng Wang,et al.  Extent of lymph node dissection improves overall survival in pT3N0 non-metastatic renal cell carcinoma patients treated with radical nephrectomy: a propensity score-based analysis , 2019, World Journal of Urology.

[24]  P. Russo,et al.  The prognostic significance of nodal disease burden in patients with lymph node metastases from renal cell carcinoma. , 2019, Urologic oncology.

[25]  F. Massari,et al.  Adjuvant Tyrosine Kinase Inhibitors in Treatment of Renal Cell Carcinoma: A Meta‐Analysis of Available Clinical Trials , 2019, Clinical genitourinary cancer.

[26]  M. Carini,et al.  Templates of Lymph Node Dissection for Renal Cell Carcinoma: A Systematic Review of the Literature , 2018, Front. Surg..

[27]  U. Capitanio,et al.  The Effect of Anatomical Location of Lymph Node Metastases on Cancer Specific Survival in Patients with Clear Cell Renal Cell Carcinoma , 2018, fsurg.

[28]  U. Capitanio,et al.  The impact of lymph node dissection and positive lymph nodes on cancer‐specific mortality in contemporary pT2‐3 non‐metastatic renal cell carcinoma treated with radical nephrectomy , 2018, BJU international.

[29]  H. G. van der Poel,et al.  Lymphatic Drainage from Renal Tumors In Vivo: A Prospective Sentinel Node Study Using SPECT/CT Imaging , 2017, The Journal of urology.

[30]  U. Capitanio,et al.  European temporal trends in the use of lymph node dissection in patients with renal cancer. , 2017, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[31]  J. Porter.  The Role of Lymphadenectomy for Renal Cell Carcinoma: Are we any Closer to an Answer? , 2017, European urology.

[32]  U. Capitanio,et al.  The rationale and the role of lymph node dissection in renal cell carcinoma , 2017, World Journal of Urology.

[33]  J. Cheville,et al.  Lymph Node Dissection is Not Associated with Improved Survival among Patients Undergoing Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma: A Propensity Score Based Analysis , 2017, The Journal of urology.

[34]  Mark W. Ball,et al.  Robotic versus laparoscopic radical nephrectomy: comparative analysis and cost considerations. , 2016, The Canadian journal of urology.

[35]  U. Capitanio,et al.  Lymph node dissection for renal cell carcinoma: what are we missing? , 2016, Current opinion in urology.

[36]  Umberto Capitanio,et al.  Renal Cancer , 2011 .

[37]  U. Capitanio,et al.  Extent of lymph node dissection at nephrectomy affects cancer‐specific survival and metastatic progression in specific sub‐categories of patients with renal cell carcinoma (RCC) , 2014, BJU international.

[38]  P. Russo,et al.  Analysis of lymph node dissection in patients with ≥7-cm renal tumors , 2014, World Journal of Urology.

[39]  J. Milner,et al.  Renal lymph nodes for tumor staging: appraisal of 871 nephrectomies with examination of hilar fat. , 2013, Archives of pathology & laboratory medicine.

[40]  Hugh J. Lavery,et al.  Decreasing Rates of Lymph Node Dissection During Radical Nephrectomy for Renal Cell Carcinoma , 2012, Annals of Surgical Oncology.

[41]  U. Capitanio,et al.  The Extent of Lymphadenectomy does Affect Cancer Specific Survival in Pathologically Confirmed T4 Renal Cell Carcinoma , 2012, Urologia.

[42]  R. Abaza,et al.  Feasibility and adequacy of robot-assisted lymphadenectomy for renal-cell carcinoma. , 2011, Journal of endourology.

[43]  Choung-Soo Kim,et al.  Reassessment of renal cell carcinoma lymph node staging: analysis of patterns of progression. , 2011, Urology.

[44]  J. Manola,et al.  Adult Urology Oncology : Adrenal / Renal / Upper Tract / Bladder Retroperitoneal Lymphadenectomy for High Risk , Nonmetastatic Renal Cell Carcinoma : An Analysis of the ASSURE ( ECOG-ACRIN 2805 ) Adjuvant Trial , 2017 .

[45]  J. Patard,et al.  Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results. , 2018, European urology.

[46]  J. Cheville,et al.  Perioperative Morbidity of Lymph Node Dissection for Renal Cell Carcinoma: A Propensity Score-based Analysis. , 2017, European Urology.

[47]  U. Capitanio,et al.  Effect of pathological high-risk features on cancer-specific mortality in non-metastatic clear cell renal cell carcinoma: a tool for optimizing patient selection for adjuvant therapy , 2017, World Journal of Urology.

[48]  D. Jacqmin,et al.  Radical nephrectomy with and without lymph-node dissection: final results of European Organization for Research and Treatment of Cancer (EORTC) randomized phase 3 trial 30881. , 2009, European urology.